CURE Pharmaceutical – Our Q2 2019 Update

We start our third quarter having acquired enabling new technology that expands our oral drug delivery capabilities, along with a significant capital infusion. We are pleased to share our post-acquisition investor presentation below, integrating the technology acquired from Chemistry Holdings in our product pipeline. Our primary focus will be on the pharmaceutical and nutraceutical cannabinoid…